Future Alinia Studies Should Be Multicenter, FDA Recommends
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Future studies of Romark’s antimicrobial Alinia should use a multicenter design, FDA advised in its review of the NDA.
You may also be interested in...
Romark Alinia Tab. Approval Expected First Half 2004; AIDS Claim To Follow
Romark expects approval in the first half of 2004 for a tablet formulation of its antimicrobial Alinia for use in immunocompetent adults and adolescents with diarrhea associated with Giardia lamblia and Cryptosporidium parvum.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011